Drug development is an arduous and expensive exercise. We seek to produce innovative compounds efficiently and effectively.

Analyst Coverage

Analyst	Firm
Jason Zhang, Ph.D.	BMO Securities
Adam Cutler	Canaccord Adams
Yaron Werber, M.D.	Citigroup
Phil Nadeau	Cowen & Co.
Michael Aberman, M.D.	Credit Suisse
Davis Bu, M.D.	Goldman Sachs
Liisa Bayko	JMP Securities
Geoffrey Meacham, Ph.D.	J.P. Morgan Securities
Terence Flynn	Lazard Capital Markets
Howard Liang, Ph.D.	Leerink Swann and Company
Ed Nash	Merriman Curhan Ford
Steve Harr, M.D.	Morgan Stanley
Alan Carr, Ph.D.	Needham & Company
Brian Abrahams, M.D.	Oppenheimer & Co. Inc.
Edward Tenthoff	Piper Jaffray
Thomas Russo	Robert W. Baird
Geoffrey Porges	Sanford Bernstein LLC
Carol Werther	Summer Street Research
Jason Kolbert	ThinkEquity
Ian Somaiya	Thomas Weisel Partners
Maged Shenuda	UBS Securities
Richard Lau	Wedbush

Vertex Pharmaceuticals Incorporated is followed by the analyst(s) listed above. Please note that any opinions, estimates or forecasts regarding Vertex Pharmaceuticals Incorporated's performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Vertex Pharmaceuticals Incorporated or its management. Vertex Pharmaceuticals Incorporated does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.